Listeners:
Top listeners:
play_arrow
Revolution Radio Your home for the best variety of Christian music
play_arrow
Heartland Newsfeed Radio Network Heartland Newsfeed Radio Network
play_arrow
Heartland Newsfeed Radio Network (Abovecast Backup) Heartland Newsfeed Radio Network
play_arrow
Home For The Holidays Radio
We'll See About That with Ron Cey Episode 157 Leave Tom Hardy Alone! Ron Cey
NEW YORK CITY (UPI) — A jury on Friday found Martin Shkreli, the pharmaceutical executive who came under scrutiny for hiking the cost of a drug by 5,000%, guilty on three counts related to securities fraud.

The fraud charges are unrelated to the drug price hike, and have to do with a Ponzi scheme he ran between 2009 and 2014 in which he bilked investors out of a total of $11 million.
He was found guilty on three out of the eight charges he faced after a week of deliberations, including securities fraud and conspiracy to commit securities and wire fraud.
“When you lie to people knowingly and intentionally to get their money, it’s a crime,” federal prosecutor Jacquelyn Kasulis said in closing arguments July 28. “And that is exactly what Martin Shkreli did. He knowingly lied over and over again to his investors.”
Prosecutors said Shkreli illegally took stock from his biotechnology firm, Retrophin Inc., and used it to pay off debts from a failed hedge fund — which is illegal. The Retrophin board of directors later sued Shkreli and he was ousted from the company for which he served as CEO.
Shkreli is accused of fraudulently reclassifying a $900,000 equity investment as a loan from his defunct hedge fund, MSMB Capital Management, after it lost millions — and made Retrophin pick up the tab.
Defense attorneys argued that Shkreli’s investors were repaid, meaning he’s already made reparations.
Prior to his arrest for securities fraud, Shkreli made headlines in August 2015 involving another company for which he served as CEO, Turing Pharmaceuticals. That company acquired Daraprim — a drug often used to treat toxoplasmosis in people with compromised immune systems, like AIDS patients — and immediately increased the price of the drug by 5,000%. The hike raised the average treatment costs from about $1,130 to $63,000 per year.
Although toxoplamosis is not considered dangerous in people who are generally healthy, for people who are pregnant or have a weakened immune system the effects of the infection can be severe. Daraprim is also used to treat malaria.
Written by UPI Writer Danielle Haynes
United Press International is an international news agency whose newswires, photo, news film, and audio services provided news material to thousands of newspapers, magazines and radio and television stations for most of the 20th century.
Written by: United Press International
found fraud guilty Martin security Shkreli
Heartland Media Group of Central Illinois & Eastern Missouri
107 W. State Street PO Box 149
Nokomis, IL 62075
Tel: (866) 420-7790
Newsletter Signup
Download Our App
Submit News
Contact Us
Heartland Newsfeed Radio Network
Revolution Radio
Home For The Holidays Radio
Deadlines
News and sports submissions: 11 p.m. Central
Advertising, legals, obituaries: 5 p.m. Central
Publication times
Late breaking news as it happens
Normal publication: 11 p.m. Central daily
Other news: Published as it’s made available
Post comments (0)